Evidence map›Paper›PMID 42989017›Full record

ReviewCell biology and toxicology2026

Fibroblast-driven matrix remodeling shapes immune exclusion in lung cancer.

Yan Wang, Lanbo Wang, Aodi Li, Lei Zhao, Lidan Liu, Xiangli Liu

Abstract readReview
In one paragraph

Review in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yan Wang *Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Lanbo Wang *Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, China.
Aodi Li *Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Lei ZhaoDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China. zhaolei@cmu.edu.cn.ORCID https://orcid.org/0009-0005-2066-1441
Lidan LiuDepartment of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, China. lldcmu@163.com.
Xiangli LiuDepartment of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, China. lxlcmu@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The lung tumor microenvironment (TME) is shaped by reciprocal interactions among cancer-associated fibroblasts (CAFs), extracellular matrix (ECM), immune cells, endothelial cells, and tumor cells. Available evidence supports an integrated sequence in which tumor-derived factors, chronic tissue injury, inflammatory cytokines, and mechanical stress generate context-dependent CAF states. Matrix-producing CAFs subsequently deposit, align, and crosslink fibrillar collagen, whereas inflammatory and antigen-presenting CAF programs regulate chemokine gradients, myeloid-cell recruitment, and local T-cell responses. These structural and biochemical changes converge to reduce vascular perfusion, restrict lymphocyte movement from stromal regions into malignant-cell nests, and promote functional immune suppression, thereby contributing to resistance to immune checkpoint blockade. The supporting evidence has been obtained from complementary systems, including single-cell and spatial profiling of human lung tumors, live imaging of human lung tumor slices, primary fibroblast-tumor cell co-cultures, three-dimensional collagen or organoid models, orthotopic xenografts, and immune-competent murine lung cancer models. Because each platform captures only part of the CAF-ECM-immune axis, conclusions should distinguish clinical association from causal evidence and specify the biological system in which a mechanism was demonstrated. Stromal signatures, collagen architecture, and spatial immune-exclusion patterns may complement tumor-intrinsic biomarkers, but their utility for treatment selection remains investigational and requires analytical standardization and prospective validation. Therapeutic development may therefore prioritize phenotype-selective CAF reprogramming and functional matrix normalization over indiscriminate fibroblast depletion, while recognizing that no single stromal feature is currently sufficient to direct clinical management. Importantly, CAF activation and ECM deposition are not uniformly tumor promoting: depending on disease stage, fibroblast state, collagen topology, and immune context, selected stromal programs may physically contain early lesions or support local immune organization. This context dependence further supports cautious, biomarker-informed evaluation of stromal interventions rather than generalized depletion. Throughout this review, spatial co-occurrence and neighborhood enrichment are treated as hypothesis-generating associations unless they are supported by temporally resolved, cell-specific perturbation and rescue experiments.

Indexed as

Cancer-Associated FibroblastsExtracellular MatrixFibroblastsLung NeoplasmsAnimalsHumansTumor MicroenvironmentCancer-associated fibroblastsECM remodelingImmune exclusionLung cancerTumor microenvironment

Identifiers

PMID42989017
PMCPMC13739994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.